Oral versus vaginal sildenafil on endometrial thickness in women with polycystic ovary syndrome receiving clomiphene citrate

Authors

Ibrahim A. S. ELnasr, Menoufia University
Mahmoud A. El-Kholy, Shebin- El-Koom Teaching HospitalFollow
Nabih I. ELkhouly, Menoufia University
Osama A. ELkelani, Menoufia University

Subject Area

Obstetrics and Gynecology

Article Type

Original Study

Abstract

Objective The aim was to compare the effect of oral and vaginal sildenafil on endometrial thickness (ET), pattern, and blood flow, in patients with polycystic ovary (PCO) syndrome receiving clomiphene citrate (CC). Background Infertility is the failure to conceive after 1 year of practicing sexual intercourse without any contraceptive measures. Patients and methods A randomized controlled clinical trial was conducted on 300 women aged between 18 and 35 years old diagnosed with PCO at the Department of Obstetrics and Gynecology at Menoufia University Hospital and Shebin Elkom Teaching Hospital from May 2019 to May 2020. By using sildenafil 20-mg coated tablets and CC 50 mg, patients were divided into group A (study group): sildenafil + CC orally. Group B (study group): sildenafil vaginally + clomiphene orally. Group C (control group): patients who were given CC orally only. Primary and secondary follow-up was done. Results There was a statistically significant difference between the study groups regarding ET and uterine blood flow, overall pregnancy rate, on tolerability with treatment, and side effect of drugs. Conclusion Vaginal sildenafil has better ET, pattern, blood flow, and high pregnancy rate.

Recommended Citation

ELnasr, Ibrahim A. S.; El-Kholy, Mahmoud A.; ELkhouly, Nabih I.; and ELkelani, Osama A. (2022) "Oral versus vaginal sildenafil on endometrial thickness in women with polycystic ovary syndrome receiving clomiphene citrate," Menoufia Medical Journal: Vol. 35: Iss. 1, Article 40.
DOI: https://doi.org/10.4103/mmj.mmj_114_21